What You Should Know:
– Pi Health, a newly independent oncology-focused clinical research company raises $30M in Series A funding led by AlleyCorp and Obvious Ventures, with additional investments from Invus Capital and leaders in oncology from across the globe.
– The company, previously incubated by BeiGene (NASDAQ: BGNE), aims to revolutionize access to innovative cancer treatments through its technology platform and global network of clinical trial sites.
Less Than 8% of Eligible Patients Participate in Trials
Cancer may not discriminate, but the current clinical trial system does. With a participation rate of less than 8% among eligible patients, valuable insights and treatment advancements are hampered. Pi Health tackles this challenge by:
- Building a Global Network: A continuously expanding network of clinical trial sites across four continents provides wider patient reach.
- Streamlined Software Platform: FICS (Front-End Interoperable Capture Software) connects sponsors and trial sites, automating tasks and ensuring high-quality data collection.
- AI-powered Solutions: Generative AI automates processes like documentation, patient matching, and data analysis, further streamlining the trial process.
Benefits for Patients and the Industry
Pi Health’s approach offers a win-win for both patients and the life sciences industry:
- Faster Patient Enrollment: Reaching a broader range of patients leads to quicker trial completion.
- Reduced Costs: Streamlined workflows minimize administrative burdens and biopharmaceutical costs.
- Improved Data Quality: Automated data collection reduces errors and improves FDA compliance.
- Faster Drug Development: Ultimately leading to the delivery of life-saving treatments to patients sooner.
